Pharmacogentic study of methyleneterahyrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences

Pharmacogenomics

Volumn 8, Issue 1, 2007, Pages 41-47

  Inoue, Sachie ^a   Hashiguchi, Masayuki ^a   Chiyoda, Takeshi ^b   Sunami, Yukiko ^b   Tanaka, Takanori ^b   Mochizuki, Mayumi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b Medical Co   (Japan)

Author keywords

5,10 methlenetetrahydrofolate reductase; Allelic frequency; Ethic difference; Gender difference; Genotype; Methotrexate; Polymorphism; Thymidlate synthase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; CYSTEINE; THYMIDYLATE SYNTHASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

5' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; HUMAN; JAPANESE; MALE; NEGRO; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; TANDEM REPEAT; ASIAN; COMPARATIVE STUDY; GENETICS; METHODOLOGY; SEXUAL DEVELOPMENT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHARMACOGENETICS; SEX CHARACTERISTICS; THYMIDYLATE SYNTHASE;

EID: 33846557901     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.1.41     Document Type: Article

References (65)

1. Japan Rheumatism Foundation. The Basic Text of Rheumatism (2nd Edition). Japan Rheumatism Foundation, Tokyo, Japan, 230-237 (2003).
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum. 46(2), 328-346 (2002).
3. Anderson JJ, Wells G, Verhoeven AC et al.: Factors predicting response to treatment in rheumatoid arthritis. Arthritis Rheum. 43(1), 22-29 (2000).
4. Hoekstra M, van Ede AE, Haagsma CJ et al.: Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 423-426 (2003).
5. Mckendry RJR, Dale P: Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J. Rheumatol. 20, 1850-1856 (1993).
6. Hughes LB, Beasley TM, Patel H et al.: Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1213-1218 (2006).
7. Furst DE, Koehnke R, Burmeister LF et al.: Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J. Rheumatol. 16, 313-320 (1989).
8. Kashiwazaki S, Ichikawa Y, Sugawara S et al.: Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis. Jpn J. Inflamm. 16(6), 437-458 (1996).
9. Frosst P, Blom HJ, Milos R et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10, 111-113 (1995).
10. Weisberg I, Tran P, Christensen B et al.: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64, 169-172 (1998).
11. Horie N, Aiba H, Oguro K et al.: Functional analysis and DNA polymorphism of the tandem repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20, 191-197 (1995).
12. Lenz H-J, Zhang W, Zahedy S: A 6 base-pair deletion in the 3′ UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors. A possible candidate gene for colorectal cancer risk. Proc. Am. Assoc. Cancer Res. 43, 3274 (2002).
13. Sadewa AH, Sunarti, Sutomo R et al.: The C677T mutation in the methylenetetrahydrofolate reductase gene among the Indonesian Japanese population. Kobe J. Med. Sci. 48(4), 137-144 (2002).
14. Marsh S, Ameyaw MM, Githang'a J et al.: Novel thymidylate synthase enhancer region alleles in African populations. Hum. Mutat. 16(6), 528 (2000).
15. Hishida A, Matsuo K, Hamajima N et al.: Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. J. Hematol. 88(2), 159-166 (2003).
16. Ulrich CM, Bigler J, Velicer CM et al.: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 9, 1381-1385 (2000).
17. Smits KM, Schouten JS, Smits LJ et al.: A review on the design and reporting of studies on drug-gene interaction. J. Clin. Epidemiol. 58(7), 651-654 (2005).
18. Hiraoka M, Kato K, Saito Y et al.: Gene-nutrient and gene-gene interactions of controlled folate intake by Japanese women. Biochem. Biophys. Res. Commun. 316, 1210-1216 (2004).
19. Matsui T, Arai H, Yuzuriha T et al.: Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke 32, 1116-1119 (2001).
20. Kowa H, Yasui K, Takeshima T et al.: The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am. J. Med. Genet. 96, 762-764 (2000).
21. Kimura H, Gejyo F, Suzuki S et al.: The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. J. Am. Soc. Nephrol. 11, 885-893 (2000).
22. Ou T, Yamakawa-Kobayashi K, Arinami T et al.: Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 137, 23-28 (1998).
23. Lwin H, Yoshiike N, Yokoyama T et al.: The relationships between plasma total homocysteine and selected atherosclerotic risk factors according to the C677T methylenetetrahydrofolate reductase gene in Japanese. Eur. J. Cardiovasc. Prev. Rehabil. 12, 182-184 (2005).
24. Ishikawa H, Ishikawa T, Miyatsu Y et al.: A polymorphism of methionine synthase reductase gene increases chromosomal damage in peripheral lymphocytes in smokers. Mutat. Res. 599, 135-143 (2006).
25. Kumagai K, Hiyama K, Oyama T et al.: Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med. 11, 593-600 (2003).
26. Kawakami K, Salonga D, Omura K et al.: Effects of polymorphic tandem repeat sequence on the in vitro translation of messenger RNA. Proc. Am. Assoc. Cancer Res. 40, 436-437 (1999).
27. Kawakami K, Omura K, Kanehira E et al.: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19, 3249-3252 (1999).
28. Kameda H, Amano K, Sekiguchi N: Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. Mod. Rheumatol. 14, 442-446 (2004).
29. Hoekstra M, van Ede AE, Haagsma CJ et al.: Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62(5), 423-426 (2003).
30. Anderson JJ, Wells G, Verhoeven AC et al.: Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 43(1), 22-29 (2000).
31. Amouzou EK, Chabi NW, Adjalla CE et al.: High prevalence of hyperhomocysteinemia related to folate deficiency and the 677C→T mutation of the gene encoding methylenetetrahydrofolate reductase in coastal West Africa. Am. J. Clin. Nutr. 79, 619-624 (2004).
32. Pegoraro RJ, Chikosi A, Rom L et al.: Methylenetetrahydrofolate reductase gene polymorphisms in black South Africans and the association with preeclampsia. Acta Obstet. Gynecol. Scand. 83, 449-454 (2004).
33. Loktionov A, Vorster H, O'Neill IK et al.: Apolipoprotein E and methylenetetrahydrofolate reductase genetic polymorphisms in relation to other risk factors for cardiovascular disease in UK Caucasians and Black South Africans. Atherosclerosis 145, 125-135 (1999).
34. Lincz LF, Scorgie FE, Kerridge I et al.: Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. Br. J. Haematol. 120, 1051-1054 (2003).
35. Rady PL, Szucs S, Grady J et al.: Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am. J. Med. Genet. 107, 162-168 (2002).
36. Mcilroy SP, Dynan LB, Lawson JT et al.: Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 33, 2351-2356 (2002).
37. Gemmati D, Ongaro A, Scapoli GL et al.: Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol. Biomarkers Prev. 13(5), 787-794 (2004).
38. Russo GT, Friso S, Jacques PF et al.: Age and gender affect the relation between methylenetetrahydrofolate reductase C677T genotype and fasting plasma homocysteine concentrations in the Framingham Offspring Study cohort. J. Nutr. 133, 3416-3421 (2003).
39. Storti S, Vittorini S, Lascone MR et al.: Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects. Clin. Chem. Lab. Med. 41(3), 276-280 (2003).
40. Zalavras ChG, Giotopoulou S, Dokou E et al.: Lack of association between the C677T mutation in the 5,10-methylenetetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece. Int. Angiol. 21, 268-271 (2002).
41. Lamgsemlehner U, Krippl P, Renner W et al.: The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk. Breast Cancer Res. Treat. 81, 169-172 (2003).
42. Hustad S, Ueland PM, Vollset SM et al.: Riboflavin as a determinant of plasma total homocysteine: effect of modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin. Chem. 46(8), 1065-1071 (2000).
43. Chambers JC, Oreland H, Thompson E et al.: Methylenetetrahydrofolate reductase 677C→T mutation and coronary heart disease risk in UK Indian Asians. Arterioscler. Thromb. Vasc. Biol. 20, 2448-2452 (2000).
44. Sazci A, Ergul E, Bayulkem K: Association of C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene in patients with essential tremor in Turkey. Move. Disord. 19(12), 1472-1476 (2004).
45. Vesela K, Pavlikova M, Janosikova B et al.: Genetic determinants of folate status in central Bohemia. Physiol. Res. 54, 295-303 (2005).
46. Rudd MF, Sellick GS, Allinson R et al.: MTHFR polymorphisms and risk of chronic lymphocystic leukemia. Cancer Epidemiol. Biomarkers Prev. 13(12), 2268-2270 (2004).
47. Ventura P, Rosa MC, Abbati G et al.: Hyperhomocysteinaemia in chronic liver diseases: role of disease stage, vitamin status and methylenetetrahydrofolate reductase genetics. Liver Int. 25, 46-56 (2005).
48. Marcucci R, Sofi F, Fedi S et al.: Thrombophilic risk factors in patients with severe carotid atherosclerosis. J. Thromb. Haemost. 3, 502-507 (2005).
49. Wang B, Fu S, Zhang G et al.: Study of the relationship between psorasis and the polymorphic site C677T of methylenetetrahydrofolate reductase. Clin. Med. Sci. J. 15(2), 119-120 (2000).
50. Lu Y, Zhao Y, Liu G et al.: Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population. Thromb. Res. 106, 7-12 (2002).
51. Sun J, Xu Y, Xue J et al.: Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. Mol. Cell. Endocrinol. 229, 95-101 (2005).
52. Wang B, Jin R, Kan R et al.: Association of MTHFR gene polymorphism C677T with susceptibility to late-onset Alzheimer's disease. J. Mol. Neurosci. 27, 23-27 (2005).
53. Song C, Xing D, Tan W et al.: Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res. 61, 3272-3275 (2001).
54. Jiang Q, Chen K, Ma XBS et al.: Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer. Cancer Detect. Prev. 29, 146-154 (2005).
55. Zhang G, Dai C: Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. Thromb. Res. 104, 187-195 (2001).
56. Ho C-H, Kuo I-TB, Kong C-W et al.: Influence of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, B vitamins and other factors on plasma homocysteine and risk of thromboembolic disease in Chinese. J. Chin. Med. Assoc. 68(12), 560-565 (2005).
57. Kim KN, Kim YJ, Chang N: Effects of the interaction between the C677T 5, 10-methylenetetrahydrofolate reductase polymorphism and serum B vitamins on homocysteine levels in pregnant women. Eur. J. Clin. Nutr. 58, 10-16 (2004).
58. Sull JW, Jee SH, Yi S et al.: The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecol Oncol. 95, 557-563 (2004).
59. Hur M, Park JY, Cho HC et al.: Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukemia and chronic myelogenous leukaemia in the Korean population. Clin. Lab. Haematol. 28, 154-159 (2006).
60. Graziano F, Kazuyuki K, Go W et al.: Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. Int. J. Cancer 112, 1010-1014 (2004).
61. Marsh S, Collie-Duguid ESR, Tao Li et al.: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58, 310-312 (1999).
62. Luo H-R, Lu X-M, Yao Y-G et al.: Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem. Genet. 40, 41-51 (2002).
63. Tan W, Miao X, Wang L et al.: Significant increase in risk of gastroesophageal cancer is associated with interaction between promoter polymorphisms in thymidylate synthase and serum folate status. Carcinogenesis 26(8), 1430-1435 (2005).
64. Gao C-M, Toshiro T, Wu J-Z et al.: Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking. Asian Pac. J. Cancer Prev. 5, 133-138 (2004).
65. Zhang J, Cui Y, Kuang G et al.: Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Carcinogenesis 25(12), 2479-2485 (2004).